发明名称 MODIFIED CATIONIC LIPOSOME ADJUVANTS
摘要 The present invention relates to the use of vaccines with adjuvants comprising cationic liposomes where neutral lipids has been incorporated into the liposomes to change the gel-liquid phase transition and thereby modifying the IgG sub-type response and enhancing the CD8 response of the liposomal adjuvant. This technology can be used to increase the production of IgG2 antibodies. This sub-type of antibodies (IgG2 in mice corresponding to IgG3 in humans) have been shown to selectively engage Fc activatory receptors on the surface of innate immune cells leading to enhanced proinflammatory responses and thereby a more efficient immune response with higher levels of protection in animal models of e.g. malaria and Chlamydia. The use of adjuvants which selectively give rise to higher levels of IgG2 antibodies will improve the effect of vaccines e.g. against intracellular infections. Furthermore the technology can be used to induce a CD8 response which has been reported to improve the effect of vaccines against e.g. HPV, HIV, influenza and cancer have been shown to selectively engage Fc activatory receptors on the surface of innate immune cells leading to enhanced proinflammatory responses and thereby a more efficient immune response with higher levels of protection in animal models of e.g. malaria and Chlamydia. The use of adjuvants which selectively give rise to higher levels of IgG2 antibodies will improve the effect of vaccines e.g. against intracellular infections. Furthermore the technology can be used to induce a CDS response which has been reported to improve the effect of vaccines against e.g. HPV, HIV, influenza and cancer.
申请公布号 US2014205656(A1) 申请公布日期 2014.07.24
申请号 US201414162511 申请日期 2014.01.23
申请人 Statens Serum Institut 发明人 Christensen Dennis;Korsholm Karen Smith;Agger Else Marie;Andersen Peter
分类号 A61K9/127;A61K39/12;A61K39/015;A61K39/145;A61K39/04 主分类号 A61K9/127
代理机构 代理人
主权项 1. A method for modifying the gel-liquid crystalline phase transition temperature (Tm) of the cationic liposomes of adjuvants comprising cationic liposomes stabilized with glycolipids by incorporating 1-Acyl-2-Acyl-sn-Glycero-3-Phosphocholine (DxPC), wherein 1-Acyl and 2-Acyl each is independently a long chain fatty acid containing from 12 to 24 carbon (C) atoms.
地址 Copenhagen S DK